Ivosidenib in patients with IDH1-mutant relapsed/refractory myelodysplastic syndrome (R/R MDS): Updated enrollment and results of a phase 1 dose-escalation and expansion substudy

This article has no abstract
Epistemonikos ID: d1196154802d194fee5afba43c3ceaf94baf5183
First added on: Feb 15, 2025